APA (7th ed.) Citation

T, P., TK, C., RJ, M., E, J., S, P., NM, T., . . . DJ, G. (2021). Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC cancer, 21(1), 904. https://doi.org/10.1186/s12885-021-08630-w

Chicago Style (17th ed.) Citation

T, Powles, et al. "Outcomes Based on Plasma Biomarkers in METEOR, a Randomized Phase 3 Trial of Cabozantinib Vs Everolimus in Advanced Renal Cell Carcinoma." BMC Cancer 21, no. 1 (2021): 904. https://doi.org/10.1186/s12885-021-08630-w.

MLA (9th ed.) Citation

T, Powles, et al. "Outcomes Based on Plasma Biomarkers in METEOR, a Randomized Phase 3 Trial of Cabozantinib Vs Everolimus in Advanced Renal Cell Carcinoma." BMC Cancer, vol. 21, no. 1, 2021, p. 904, https://doi.org/10.1186/s12885-021-08630-w.